Costa, B.A.; Dima, D.; Mark, T.; Sadek, N.L.; Ijioma, S.; Ray, D.; Goel, U.; Dranitsaris, G.; Sheng, T.; Moshier, E.;
et al. Impact of Prior Selinexor Exposure on Outcomes of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Exploratory Analysis. J. Clin. Med. 2025, 14, 1316.
https://doi.org/10.3390/jcm14041316
AMA Style
Costa BA, Dima D, Mark T, Sadek NL, Ijioma S, Ray D, Goel U, Dranitsaris G, Sheng T, Moshier E,
et al. Impact of Prior Selinexor Exposure on Outcomes of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Exploratory Analysis. Journal of Clinical Medicine. 2025; 14(4):1316.
https://doi.org/10.3390/jcm14041316
Chicago/Turabian Style
Costa, Bruno Almeida, Danai Dima, Tomer Mark, Norah Layla Sadek, Stephen Ijioma, David Ray, Utkarsh Goel, George Dranitsaris, Tianxiang Sheng, Erin Moshier,
and et al. 2025. "Impact of Prior Selinexor Exposure on Outcomes of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Exploratory Analysis" Journal of Clinical Medicine 14, no. 4: 1316.
https://doi.org/10.3390/jcm14041316
APA Style
Costa, B. A., Dima, D., Mark, T., Sadek, N. L., Ijioma, S., Ray, D., Goel, U., Dranitsaris, G., Sheng, T., Moshier, E., Mouhieddine, T. H., Khouri, J., & Rossi, A.
(2025). Impact of Prior Selinexor Exposure on Outcomes of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Exploratory Analysis. Journal of Clinical Medicine, 14(4), 1316.
https://doi.org/10.3390/jcm14041316
